Roche Expects Sales, Earnings Growth

Roche Expects Sales, Earnings Growth After Better-Than-Expected Results
The company expects sales and core earnings to keep growing this year after beating analysts’ expectations for 2024, and the CEO said it remained committed to keeping its R&D spending broadly flat in 2025.
We had a strong 2024 and expect momentum to carry into 2025, says Roche CEO
Thomas Schinecker, the CEO of Roche, discusses the Swiss company's full-year earnings. Boat packed with migrants intercepted amid Trump's mass deportation effort
Roche Sees Profit Growth Outpacing Sales With Deals Ahead
Roche Holding AG said profit will probably outpace sales growth this year as the Swiss drugmaker works to keep research costs in check and looks for deals to build its pipeline of experimental medicines.
Roche Expected to Report Higher Earnings, Sales -- Earnings Preview
EARNINGS FORECAST: Roche's core earnings per share are expected to come in at 18.59 francs, according to the Visible Alpha consensus. For 2023, the company reported core EPS of 18.57 francs. As of Monday morning trade in Europe, the stock is up 9.2% since the start of 2025, and up 13% over the last 12 months.
Roche sees high single-digit core profit growth in 2025
Roche said on Thursday it is targeting a continued increase in adjusted earnings per share (EPS) at a high single-digit percentage this year, helped by lower costs and growth from drugs such as eye treatment Vabysmo and cancer drug Phesgo.
ENDPOINTS NEWS42m
Roche aims for de­risked deals and ruth­less port­fo­lio cuts in 2025
Roche CEO Schinecker outlines M&A focus on derisked assets, discusses China opportunities, and announces cancellation of four ...
FierceBiotech3h
Roche drops HER2 bispecific, Xencor-partnered cytokine from early-phase pipeline
Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked up from Xencor. | Roche has given two early-phase bispecifics the heave-ho ...
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Roche Holding AG (OtherRHHVF) and Sanofi (OtherSNYNF)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nurix Therapeutics (NRIX – Research Report), ...
FiercePharma1d
Roche's breast cancer entrant Itovebi bolsters clinical profile with overall survival win
Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...
Roche receives FDA 510(k) clearance for the first blood test in the U.S. measuring Lp(a) in molar units
Gen.2 Molarity assay has received 510(k) clearance from the United States Food and Drug Administration (FDA). This will be the first 510(k) cleared test of its kind available in the U.S. measuring ...
Roche FY24 Core Operating Profit Rises; Sales Up 7% At CER
Roche (RHHBY) reported that its fiscal 2024 IFRS net income decreased by 19%, or 26% in Swiss francs, to 9.2 billion francs, mainly ...
Pharm Exec20h
Roche Appoints Wafaa Mamilli as Chief Digital Technology Officer
Effective February 10, 2025, Mamilli will assume global responsibility for the Informatics function for the Roche Group.
Daily2h
Roche Pharma India appoints Rajwinder (Rajji) Mehdwan as new Country General Manager
Mumbai: Roche Pharma India has announced the appointment of Rajwinder (Rajji) Mehdwan as country General Manager, effective 1 ...
Christopher Roche Art | Made in Arizona
In this Made in Arizona, we're highlighting local artist Christopher Roach of Mesa. He uses art to showcase the beauty of ...